Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
432.16M | 385.69M | 270.60M | 50.04M | 0.00 | 0.00 | Gross Profit |
395.36M | 352.39M | 244.53M | 44.84M | -1.16M | -77.72K | EBIT |
-270.27M | -280.56M | -231.82M | -176.50M | -124.71M | -99.14M | EBITDA |
-266.13M | -272.60M | -224.99M | -174.23M | -123.55M | -99.06M | Net Income Common Stockholders |
-278.27M | -287.22M | -239.24M | -197.77M | -134.94M | -105.39M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
331.44M | 315.35M | 386.19M | 200.84M | 86.47M | 183.88M | Total Assets |
545.73M | 568.50M | 588.24M | 331.48M | -338.36M | 186.13M | Total Debt |
189.43M | 192.96M | 186.37M | 94.68M | 49.71M | 50.12M | Net Debt |
-142.01M | -122.40M | -199.82M | -106.16M | -36.76M | -133.75M | Total Liabilities |
401.69M | 511.48M | 397.26M | 221.92M | 70.84M | 72.34M | Stockholders Equity |
144.04M | 57.02M | 190.98M | 109.56M | -409.20M | -278.80M |
Cash Flow | Free Cash Flow | ||||
-118.25M | -128.68M | -145.66M | -117.21M | -108.53M | -78.50M | Operating Cash Flow |
-118.32M | -128.41M | -145.08M | -116.51M | -108.23M | -78.46M | Investing Cash Flow |
-510.00K | -270.00K | -582.00K | -53.70M | -307.55K | -45.89K | Financing Cash Flow |
88.30M | 57.84M | 331.01M | 284.58M | 11.13M | 42.41M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $3.78B | 31.80 | 13.90% | ― | 247.53% | 118.34% | |
68 Neutral | $7.22B | ― | -72.73% | ― | ― | -157.53% | |
55 Neutral | $3.82B | 19.61 | -23.61% | ― | 59.15% | -1881.09% | |
53 Neutral | $5.25B | 3.24 | -45.38% | 2.81% | 16.79% | -0.06% | |
50 Neutral | $8.24B | ― | -47.71% | ― | 99.19% | 48.43% | |
49 Neutral | $5.30B | ― | -282.16% | ― | 72.16% | 9.65% | |
36 Underperform | $3.82B | ― | 435.49% | ― | 412.21% | 1.75% |
On May 27, 2025, Axsome Therapeutics announced a settlement agreement with Hetero Labs Ltd. to resolve patent litigation regarding Axsome’s product SUNOSI (solriamfetol). The agreement allows Hetero to sell a generic version of SUNOSI in the U.S. starting in 2040, contingent on FDA approval and other conditions. This settlement is subject to review by U.S. regulatory authorities, and similar litigation with other parties remains pending.
The most recent analyst rating on (AXSM) stock is a Buy with a $175.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.
On May 8, 2025, Axsome Therapeutics entered into a $570 million loan agreement with Blackstone, replacing its previous loan with Hercules Capital. This agreement, which includes a term loan and revolving credit facility, is expected to reduce interest expenses and support Axsome’s growth and profitability goals. The company also completed a private placement of common stock with Blackstone, raising approximately $15 million. These financial moves aim to enhance Axsome’s operational and financial agility, supporting its mission to improve patient outcomes in CNS disorders.
The most recent analyst rating on (AXSM) stock is a Buy with a $175.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.